BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 22806958)

  • 1. Treatment response monitoring in patients with gastrointestinal stromal tumor using diffusion-weighted imaging: preliminary results in comparison with positron emission tomography/computed tomography.
    Gong NJ; Wong CS; Chu YC; Gu J
    NMR Biomed; 2013 Feb; 26(2):185-92. PubMed ID: 22806958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of measurements from diffusion weighted MR imaging and FDG PET/CT in GIST patients: ADC versus SUV.
    Wong CS; Gong N; Chu YC; Anthony MP; Chan Q; Lee HF; Chu KM; Khong PL
    Eur J Radiol; 2012 Sep; 81(9):2122-6. PubMed ID: 21955604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of 18F-FDG PET/CT and diffusion-weighted MR imaging as a predictor of histologic response to neoadjuvant chemotherapy: preliminary results in osteosarcoma.
    Byun BH; Kong CB; Lim I; Choi CW; Song WS; Cho WH; Jeon DG; Koh JS; Lee SY; Lim SM
    J Nucl Med; 2013 Jul; 54(7):1053-9. PubMed ID: 23670899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
    Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
    Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion-weighted magnetic resonance imaging in metastatic gastrointestinal stromal tumor (GIST): a pilot study on the assessment of treatment response in comparison with 18F-FDG PET/CT.
    Schmidt S; Dunet V; Koehli M; Montemurro M; Meuli R; Prior JO
    Acta Radiol; 2013 Oct; 54(8):837-42. PubMed ID: 23761549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
    Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
    Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between standardized uptake value and apparent diffusion coefficient of neoplastic lesions evaluated with whole-body simultaneous hybrid PET/MRI.
    Rakheja R; Chandarana H; DeMello L; Jackson K; Geppert C; Faul D; Glielmi C; Friedman KP
    AJR Am J Roentgenol; 2013 Nov; 201(5):1115-9. PubMed ID: 24147485
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imatinib and beyond in gastrointestinal stromal tumors: A radiologist's perspective.
    Tirumani SH; Jagannathan JP; Krajewski KM; Shinagare AB; Jacene H; Ramaiya NH
    AJR Am J Roentgenol; 2013 Oct; 201(4):801-10. PubMed ID: 24059369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increasing the accuracy of volume and ADC delineation for heterogeneous tumor on diffusion-weighted MRI: correlation with PET/CT.
    Gong NJ; Wong CS; Chu YC; Guo H; Huang B; Chan Q
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):407-13. PubMed ID: 23958150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion-weighted MRI in early chemotherapy response evaluation of patients with diffuse large B-cell lymphoma--a pilot study: comparison with 2-deoxy-2-fluoro- D-glucose-positron emission tomography/computed tomography.
    Wu X; Kellokumpu-Lehtinen PL; Pertovaara H; Korkola P; Soimakallio S; Eskola H; Dastidar P
    NMR Biomed; 2011 Dec; 24(10):1181-90. PubMed ID: 21387451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrointestinal stromal tumors treated with imatinib mesylate: apparent diffusion coefficient in the evaluation of therapy response in patients.
    Tang L; Zhang XP; Sun YS; Shen L; Li J; Qi LP; Cui Y
    Radiology; 2011 Mar; 258(3):729-38. PubMed ID: 21193597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results.
    Lambrecht M; Vandecaveye V; De Keyzer F; Roels S; Penninckx F; Van Cutsem E; Filip C; Haustermans K
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):863-70. PubMed ID: 21398048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to neoadjuvant therapy in locally advanced rectal cancer: assessment with diffusion-weighted MR imaging and 18FDG PET/CT.
    Ippolito D; Monguzzi L; Guerra L; Deponti E; Gardani G; Messa C; Sironi S
    Abdom Imaging; 2012 Dec; 37(6):1032-40. PubMed ID: 22270580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization.
    Piduru SM; Schuster DM; Barron BJ; Dhanasekaran R; Lawson DH; Kim HS
    J Vasc Interv Radiol; 2012 Jul; 23(7):943-8. PubMed ID: 22609292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings.
    Choi H; Charnsangavej C; de Castro Faria S; Tamm EP; Benjamin RS; Johnson MM; Macapinlac HA; Podoloff DA
    AJR Am J Roentgenol; 2004 Dec; 183(6):1619-28. PubMed ID: 15547201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study.
    Wu X; Korkola P; Pertovaara H; Eskola H; Järvenpää R; Kellokumpu-Lehtinen PL
    Eur J Radiol; 2011 Aug; 79(2):e117-21. PubMed ID: 21596501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic and prognostic value of pretreatment SUV in 18F-FDG/PET in breast cancer: comparison with apparent diffusion coefficient from diffusion-weighted MR imaging.
    Baba S; Isoda T; Maruoka Y; Kitamura Y; Sasaki M; Yoshida T; Honda H
    J Nucl Med; 2014 May; 55(5):736-42. PubMed ID: 24665089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.